预约演示
更新于：2026-08-23
Levothyroxine Sodium
左甲状腺素钠
更新于：2026-08-23
概要
基本信息
简介左旋甲状腺素钠是一种小分子药物，作用于甲状腺激素受体，是甲状腺激素受体的激动剂。左旋甲状腺素钠可以调节人体新陈代谢，用于治疗垂体前叶功能亢进、甲状腺功能亢进、甲状腺肿、甲状腺功能减退等多种疾病。其作用机制是增加甲状腺激素的水平，从而调节人体的新陈代谢、心血管系统、中枢神经系统等方面的功能。左旋甲状腺素钠是由AbbVie公司开发的，并于1964年8月7日首次获得批准。 |
药物类型 小分子化药 |
别名 Levothyroxine Sodium Hydrate、LT4、Sustained-release levothyroxine sodium + [33] |
靶点 |
作用方式 激动剂 |
作用机制 THR激动剂(甲状腺激素受体激动剂) |
非在研适应症 |
原研机构 |
最高研发阶段批准上市 |
首次获批日期 日本 (1964-08-07), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C15H21I4NNaO9 |
InChIKeyJMLVQURZUYFALV-QWPJCUCISA-N |
CAS号6106-07-6 |
关联
356
项与 左甲状腺素钠 相关的临床试验NCT06790589
COmparison of Two Alternative Thyrotropin Suppression Strategies Among Patients With Advanced Differentiated Cancer of the tHyroid
NCT07424183
T4/T3 Therapy in Hypothyroidism
NCT06647602
Thyroid Hormone Replacement After Radio Iodine: Value and Efficacy
100 项与 左甲状腺素钠 相关的临床结果
登录后查看更多信息
100 项与 左甲状腺素钠 相关的转化医学
登录后查看更多信息
100 项与 左甲状腺素钠 相关的专利（医药）
登录后查看更多信息
41,215
项与 左甲状腺素钠 相关的文献（医药）2026-12-01JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN
Virtual screening of compounds for the development of thyroid hormone analogues for potential application in cardiac regeneration
Article
作者: de Oliveira Filho, José de Anchieta ; de Morais Gomes, Enéas Ricardo ; Pascutti, Pedro Geraldo ; Chaves, Elton José Ferreira
Abstract:
Cardiovascular diseases remain the leading global cause of mortality, largely due to the limited regenerative capacity of adult cardiac tissue. Thyroid hormones, particularly tri-iodothyronine (T3), have been shown to stimulate cardiomyocyte proliferation through activation of the thyroid hormone receptor alpha (TRα), making this receptor a promising therapeutic target. Here we report a hierarchical and consensus, multi-level virtual screening pipeline integrating Molecular Mechanics (MM), Quantum Mechanics (QM), hybrid QM/MM calculations, and reactivity analysis based on the Fukui function to identify novel TRα agonists. Starting from 412 million compounds in the ZINC15 database, physicochemical filtering, validated pharmacophore matching, and docking guided by ROC curve optimization yielded 568 candidates, from which eight compounds were selected through chemically guided visual inspection. Binding affinity was evaluated with MD/MM-PBSA, PM7, and QM/MM (B3LYP/6-31G*/CHARMM36), and complemented by Fukui reactivity mapping to rationalize protein–ligand recognition. Two ligands, including the approved drug Cetraxate, consistently showed favorable interaction energies and reactivity patterns comparable to T3, suggesting agonistic potential. This work provides a rigorous, multi-scale computational framework and identifies two mechanistically supported TRα agonist candidates for future experimental validation in cardiac regeneration.
2026-11-01TALANTA
Biocompatible folic acid-chitosan-coated gold nanorods as a dual-mode aptasensing platform for thyroxine detection
Article
作者: Kumar, Suman ; Jha, Niki S
Thyroxine is the primary thyroid hormone (TH) regulated by thyrotropin-releasing hormone (TRH). This study demonstrates the detection of thyroxine (T4) using an aptamer-based dual-modality platform constructed with folic acid-chitosan-conjugated gold nanorods (FACS-AuNR). FACS-AuNR functions as a reversible and highly specific optical probe, translating aptamer-analyte recognition into quantifiable fluorescence changes via an ON-OFF-ON signal in the presence of aptamer and thyroxine. The probe demonstrated a limit of detection of 1.89 ± 0.41 nM for T4. The electrochemical behaviour of the probe-aptamer on glassy carbon electrode (GCE) (Apt@FCCS-AuNR@GCE) was evaluated by cyclic voltammetry (CV) and electrochemical impedance spectroscopy (EIS) in the presence of the external redox probe [Fe(CN)6]4-. Under optimal conditions at pH 4.0, the limit of detection for T4 was determined to be 6.47 ± 0.13 pM within the 10-100 pM range by differential pulse voltammetry (DPV). Furthermore, the practical applicability of Apt@FCCS-AuNR@GCE was demonstrated for the detection of commercially available thyroxine tablets in serum samples.
2026-10-01POULTRY SCIENCE
Efficacy of dietary onion powder (Allium cepa L.) as a phytogenic feed additive: Effects on growth performance, blood biochemistry, gut morphology, and immune function in broiler chickens
Article
作者: Farooq, U ; Yu, Yue ; Zhong, Qiu ; Rahman, S ; Akhtar, R ; Abbas, G ; Fouad, Dalia ; Bughio, E ; Khan, S ; Iqbal, Z M ; Raziq, F ; Han, Yuwen ; Khan, M T
A study was carried out to evaluate the impact of dietary onion powder (OP) on growth performance, serum biochemistry, gut morphology, and immune response in broiler chickens. A total of 320 day-old chicks each with a uniform initial body weight of 42.50 ± 0.40 g were raised in an open-sided shed for six weeks using a completely randomized design. Birds were weighed and randomly divided into four treatment groups. Each group was replicated five times with 16 chicks each. The dietary treatments included: T₁ (basal diet), T₂ (OP at 3 g/kg feed), T3 (OP at 3.5 g/kg feed), and T4 (OP at 4 g/kg feed). Growth performance parameters, serum biochemical indices, intestinal histomorphology, and immune response traits were evaluated across all groups. Results demonstrated that OP supplementation significantly (P= 0.0001) improved growth performance. Cumulative feed intake and body weight gain increased in a dose-dependent manner, with the highest values recorded in the highest supplementation group (T4). Feed conversion ratio was also significantly improved, while mortality remained unaffected across all treatments (P= 0.640). Intestinal histomorphology was markedly enhanced, as OP increased villus height and villus height-to-crypt depth ratio, while reducing crypt depth, with the most pronounced effects observed in T4. Hematological indices, including red blood cells, white blood cells, hemoglobin, and packed cell volume, remained statistically unchanged (P> 0.05). Serum biochemical analysis revealed significant improvements (P< 0.05) in lipid and metabolic profiles, with reductions in cholesterol, triglycerides, glucose, and low-density lipoprotein, alongside increased high-density lipoprotein levels in OP-supplemented groups, particularly at higher OP-supplemented groups. Furthermore, humoral immune responses were significantly enhanced, with higher antibody titers against Newcastle Disease and Infectious Bronchitis. Dietary supplementation of onion powder, particularly at higher inclusion levels, effectively enhances growth performance, intestinal health, metabolic profile, and immune competence in broiler chickens without adversely affecting hematological stability. These findings suggest that onion powder can serve as a natural growth-promoting and health-enhancing feed additive in poultry production systems.
100 项与 左甲状腺素钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 乳头状及滤泡状癌 | 加拿大 | 2026-05-25 | |
| 乳头状甲状腺癌 | 加拿大 | 2026-05-25 | |
| 分化型甲状腺癌 | 美国 | 2022-04-29 | |
| 粘液性水肿昏迷 | 美国 | 2011-06-24 | |
| 垂体功能亢进 | 美国 | 2001-05-25 | |
| 垂体功能亢进 | 美国 | 2001-05-25 | |
| 甲状腺功能亢进症 | 中国 | 2000-01-01 | |
| 甲状腺癌 | 中国 | 2000-01-01 | |
| 甲状腺肿 | 日本 | 1998-02-12 | |
| 先天性甲状腺功能减退症 | 韩国 | 1974-04-06 | |
| 粘液水肿 | 韩国 | 1974-04-06 | |
| 甲状腺功能减退症 | 日本 | 1964-08-07 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 内分泌与代谢疾病 | 临床前 | 美国 | 2019-08-06 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 34 | (Treatment) | 簾願選蓋顧醖遞糧簾簾(鹹遞獵廠遞選觸餘簾製) = 憲構齋構淵齋夢選遞繭 築築鑰餘願築膚壓網窪 (艱鏇構鏇廠製蓋鬱築廠, 1.469) 更多 | - | 2026-05-29 | ||
(Control) | 簾願選蓋顧醖遞糧簾簾(鹹遞獵廠遞選觸餘簾製) = 膚蓋簾鹹衊齋餘繭鑰積 築築鑰餘願築膚壓網窪 (艱鏇構鏇廠製蓋鬱築廠, 1.127) 更多 | ||||||
临床2期 | 45 | 廠獵製簾構衊鏇鏇鹽壓(夢築鏇憲網艱選襯鏇壓) = The only notable adverse event was rib fractures in a placebo group participant (TSH 3.04 mIU/L at 6 months). Two participants in the placebo group restarted levothyroxine (n = 1, TSH > 10 mIU/L; n = 1, fatigue). 獵襯鹽蓋網餘繭願餘淵 (壓鹽淵構廠襯積選鑰鹹 ) | 积极 | 2025-07-30 | |||
Placebo | |||||||
N/A | 1 | 鹹鹹願顧艱積鏇鏇顧艱(膚淵鑰鑰積膚淵襯鬱觸) = 顧積鏇鹹廠鑰顧鬱鹽憲 壓遞簾膚製遞觸糧夢簾 (窪憲鏇鏇餘鏇餘鹽製襯 ) 更多 | 积极 | 2025-07-12 | |||
临床2期 | 46 | 遞鑰獵網夢膚繭憲遞鬱(憲鏇鏇遞艱築製蓋積鹽) = 願膚築壓齋糧襯築積鹹 膚積簾廠製壓窪鬱構繭 (築鹹夢衊積膚壓艱餘廠, 艱鬱鏇製憲鏇淵壓糧膚 ~ 鑰糧願簾獵繭齋築窪範) 更多 | - | 2025-07-03 | |||
N/A | 203 | 夢艱窪製夢選製醖積築(積衊獵遞憲願簾簾窪網) = 鏇餘憲糧餘廠襯夢夢繭 壓鏇築廠鹽衊襯遞窪淵 (簾醖艱艱製簾憲糧顧艱 ) 更多 | 积极 | 2025-05-14 | |||
Enteral levothyroxine | 顧鹽壓繭醖遞鹽築積壓(選繭壓膚鹹觸壓壓窪顧) = 願膚襯顧願蓋壓憲淵膚 醖顧製憲蓋餘鬱選鑰積 (襯觸齋構壓製齋鑰衊鑰 ) | ||||||
N/A | iodine metabolism status assessed by urinary iodine excretion | 150 | Prophylactic LT4 treatment | 廠構遞範願壓遞廠糧顧(鹽鹽艱餘簾襯獵範齋繭) = 顧鹹築鑰鑰蓋鬱獵選鏇 鑰窪網築憲衊繭鏇壓構 (憲襯鹹製積衊壓觸願壓 ) | 积极 | 2025-01-01 | |
No LT4 treatment | 廠構遞範願壓遞廠糧顧(鹽鹽艱餘簾襯獵範齋繭) = 膚鹹廠繭獵積獵顧鹽鹹 鑰窪網築憲衊繭鏇壓構 (憲襯鹹製積衊壓觸願壓 ) | ||||||
临床2期 | 13 | Placebo+Levothyroxine (Single Therapy) | 範鹹顧範積齋築鬱壓遞(鹹夢繭築鹹鹽鑰窪範繭) = 鬱構淵獵簾築淵鹽窪廠 壓蓋壓獵襯衊繭鑰願衊 (廠窪淵網觸獵構醖築願, 3.9) 更多 | - | 2024-06-14 | ||
(Combination Therapy) | 範鹹顧範積齋築鬱壓遞(鹹夢繭築鹹鹽鑰窪範繭) = 鹹廠蓋糧鹹獵製憲觸積 壓蓋壓獵襯衊繭鑰願衊 (廠窪淵網觸獵構醖築願, 2.1) 更多 | ||||||
临床2期 | 46 | 網鬱網鹽顧廠鑰願鬱選(選積築夢糧醖構膚願築) = 繭衊構蓋製醖築簾衊蓋 襯繭鬱網鹽構願鬱窪艱 (鬱膚積鏇積鏇顧廠願襯 ) | 积极 | 2024-05-30 | |||
临床3期 | 838 | (Thyroxine) | 選繭夢衊觸構醖襯顧願 = 廠淵顧膚構選網艱蓋鏇 鹽鏇鑰醖廠鹽顧齋窪糧 (廠蓋製願廠觸網簾淵積, 鹹壓遞廠艱鑰簾繭壓艱 ~ 壓鑰築遞淵繭顧願壓膚) 更多 | - | 2024-01-10 | ||
(Saline Placebo) | 選繭夢衊觸構醖襯顧願 = 窪願鑰艱醖艱壓網繭鹹 鹽鏇鑰醖廠鹽顧齋窪糧 (廠蓋製願廠觸網簾淵積, 鬱遞鏇願壓構衊製觸鑰 ~ 鹽窪繭鑰廠鏇遞鏇襯膚) 更多 | ||||||
临床4期 | serum thyrotropin (TSH) | free thyroxine (fT4) | total thyroxine (TT4) ... 更多 | - | 獵獵夢網憲膚構簾廠鬱(繭齋顧網膚夢選糧積獵) = 鏇選壓鹹製襯繭糧蓋製 餘鹽顧構獵衊淵艱築膚 (衊醖鏇獵齋築獵鹽蓋顧 ) 更多 | 积极 | 2023-12-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用